Eloralintide vs Mazdutide
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: GSBR-1290, Structure GSBR-1290
Eloralintide (Eli Lilly code LY3841136) is an investigational, long-acting, selective amylin receptor agonist given as a once-weekly subcutaneous injection for obesity. Amylin is the satiety hormone your pancreas releases alongside insulin, and eloralintide is built to mimic it without the gut side effects that sink most appetite drugs. It is not approved anywhere yet, but it has cleared Phase 1 and a 263-person Phase 2 trial with weight loss up to roughly 20 percent, and Lilly has said it is moving into Phase 3.
Also: IBI362, LY3305677
Mazdutide is a GLP-1 and glucagon dual agonist, which puts it between semaglutide (GLP-1 only) and retatrutide (GLP-1, GIP and glucagon). It is built on oxyntomodulin, a natural gut hormone that hits both receptors, rather than on a GLP-1 backbone. It is furthest along in China, where it is approved for both weight management and type 2 diabetes. Western approval has not happened.
Key Comparison Insights
- Both peptides belong to the Weight Loss category, suggesting similar primary applications.
Detailed Comparison
| Attribute | Eloralintide | Mazdutide |
|---|---|---|
| Category | Weight Loss | Weight Loss |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Amylin (also called IAPP) is a hormone co-secreted with insulin after you eat, and it tells your brain you are full and slows how fast your stomach empties. Eloralintide is engineered to selectively switch on the amylin receptor, which is the calcitonin receptor paired with a receptor-activity-modifying protein (RAMP), in appetite-control regions of the brainstem and hypothalamus. The result is reduced food intake and earlier satiety. The reason this class is interesting is that, unlike GLP-1 drugs such as semaglutide and tirzepatide, amylin agonists seem to drive weight loss with much less nausea and vomiting, which is what the eloralintide trials reported. Whether it preserves more lean mass than GLP-1 drugs is a real hypothesis being tested, not a settled fact. | Two receptors, two jobs. The GLP-1 arm does the familiar work: it suppresses appetite, slows gastric emptying and improves glucose-dependent insulin release. The glucagon arm is the interesting half, because glucagon is normally thought of as the hormone that raises blood sugar. At these doses the intent is to exploit glucagon's other effects, increasing energy expenditure and pushing the liver to burn fat, while the GLP-1 arm keeps blood glucose in check and cancels out glucagon's hyperglycemic tendency. That balance is the whole design: glucagon supplies extra fat burning that GLP-1 alone cannot, and GLP-1 supplies the safety margin that makes adding glucagon viable. Reported reductions in liver fat are consistent with the glucagon component doing what it is meant to. |
| Common Dosing | 120-240mg once daily (oral) Once daily | 4-6 mg weekly Once weekly |
| Administration | Oral tablet | Subcutaneous injection, once weekly |
| Typical Duration | 36 weeks in Phase 2 trials | Ongoing weekly use in trials, typically assessed at 24 to 48 weeks |
| Best Time to Take | - | Same day each week, morning preferred |
Possible Side Effects May vary by individual |
|
|
| Research Summary | This is one of the few research peptides on this site with genuinely strong, recent human data. The Phase 1 proof-of-concept study (Eli Lilly, published 2026) randomized 100 adults with obesity across five ascending dose cohorts and reported dose-proportional pharmacokinetics and least-squares mean weight reductions of 2.6 to 11.3 percent by week 12, with notably low gastrointestinal side effects (nausea 8 percent, vomiting 4 percent). In November 2025 Lilly announced topline Phase 2 results in 263 adults with obesity or overweight: at 48 weeks all dose arms beat placebo, with mean weight loss from about 9.5 percent at the lowest dose up to 20.1 percent at 9 mg, versus 0.4 percent on placebo, plus improvements in waist circumference, blood pressure, lipids, and glycemic markers. The most common adverse events were mild-to-moderate nausea and fatigue. The honest caveat: full peer-reviewed Phase 2 data and any head-to-head against tirzepatide are still pending, and there are no long-term safety or cardiovascular outcome results yet because Phase 3 is only just beginning. So the early efficacy signal is impressive, but durability and long-term safety are unproven. | The pivotal trial is GLORY-1, published in the New England Journal of Medicine in 2025: 610 Chinese adults with overweight or obesity over 48 weeks. Mean weight reduction was 11.0 percent at 4 mg and 14.0 percent at 6 mg, alongside improvements in liver fat, blood pressure and lipids. A 9 mg dose has since been studied in phase 2 (about 12.8 percent at 24 weeks) and is in phase 3. Tolerability followed the pattern of the whole class, dominated by dose-dependent nausea, vomiting and diarrhea during titration. One caveat matters when reading these numbers: GLORY-1 enrolled a population with a mean BMI of 31.1, against roughly 38 in the Western trials of semaglutide and tirzepatide, so the percentages are not directly comparable to SURMOUNT-1 or STEP-1 results. There is no completed Western phase 3 program, so neither the FDA nor the EMA has assessed it, and meaningful head-to-head data against tirzepatide or retatrutide does not exist. |
Frequently Asked Questions: Eloralintide vs Mazdutide
What is the difference between Eloralintide and Mazdutide?
Eloralintide is a weight loss peptide that eloralintide (eli lilly code ly3841136) is an investigational, long-acting, selective amylin receptor agonist given as a once-weekly subcutaneous injection for obesity. amylin is the satiety hormone your pancreas releases alongside insulin, and eloralintide is built to mimic it without the gut side effects that sink most appetite drugs. it is not approved anywhere yet, but it has cleared phase 1 and a 263-person phase 2 trial with weight loss up to roughly 20 percent, and lilly has said it is moving into phase 3. Mazdutide is a weight loss peptide that mazdutide is a glp-1 and glucagon dual agonist, which puts it between semaglutide (glp-1 only) and retatrutide (glp-1, gip and glucagon). it is built on oxyntomodulin, a natural gut hormone that hits both receptors, rather than on a glp-1 backbone. it is furthest along in china, where it is approved for both weight management and type 2 diabetes. western approval has not happened. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Eloralintide or Mazdutide?
Neither is universally "better" - the choice depends on your specific goals. Eloralintide is typically used for weight loss purposes, while Mazdutide is used for weight loss. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Eloralintide and Mazdutide be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Eloralintide and Mazdutide together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.